Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Gross Profit (2016 - 2025)

Cytosorbents (CTSO) has disclosed Gross Profit for 14 consecutive years, with $6.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Profit rose 26.82% year-over-year to $6.7 million, compared with a TTM value of $26.5 million through Sep 2025, up 12.56%, and an annual FY2024 reading of $25.1 million, up 14.45% over the prior year.
  • Gross Profit was $6.7 million for Q3 2025 at Cytosorbents, down from $6.8 million in the prior quarter.
  • Across five years, Gross Profit topped out at $9.3 million in Q2 2021 and bottomed at $3.6 million in Q3 2022.
  • Average Gross Profit over 5 years is $6.3 million, with a median of $6.4 million recorded in 2022.
  • The sharpest move saw Gross Profit plummeted 50.43% in 2022, then soared 55.0% in 2023.
  • Year by year, Gross Profit stood at $7.7 million in 2021, then fell by 24.84% to $5.8 million in 2022, then fell by 15.36% to $4.9 million in 2023, then skyrocketed by 38.97% to $6.8 million in 2024, then decreased by 1.56% to $6.7 million in 2025.
  • Business Quant data shows Gross Profit for CTSO at $6.7 million in Q3 2025, $6.8 million in Q2 2025, and $6.2 million in Q1 2025.